Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CDC42 | P60953 | 1/20 | 0.41 |
| ▸ | RAC1 | P63000 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9298556 | 0.88 | NPSR1 (0.44) | NPSR1CYP1A2TSHRALDH1A1MAPT | |
| SCHEMBL7567010 | 0.84 | ATM (0.42) | ALDH1A1KMT2AKDM4EL3MBTL1LMNA | |
| SCHEMBL3232420 | 0.84 | ATM (0.42) | ALDH1A1KMT2AKDM4EL3MBTL1LMNA | |
| SCHEMBL8405171 | 0.84 | ATM (0.42) | ALDH1A1KMT2AKDM4EL3MBTL1LMNA | |
| SCHEMBL7570004 | 0.83 | PPARG (0.44) | CYP1A2MAPTPOLBMEN1KMT2A | |
| SCHEMBL730392 | 0.79 | PRSS1 (0.38) | TSHRALDH1A1MAPTKDM4ECA1 | |
| SCHEMBL11517879 | 0.78 | NPSR1 (0.49) | NPSR1LDHAAKR1C3AKR1C2PTGS2 | |
| SCHEMBL3829660 | 0.77 | LDHA (0.52) | NPSR1LDHAAKR1C3AKR1C2PTGS2 | |
| SCHEMBL17295985 | 0.77 | LDHA (0.52) | NPSR1LDHAAKR1C3AKR1C2PTGS2 | |
| SCHEMBL17295989 | 0.77 | LDHA (0.52) | NPSR1LDHAAKR1C3AKR1C2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580429-B2 | Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2017-02-28 | — | — | US | disclosed |
| US-20150099769-A1 | PYRROLO[3,2-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2015-04-09 | — | — | US | disclosed |
| US-8859568-B2 | Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2014-10-14 | — | — | US | disclosed |
| EP-1824855-B1 | Novel pyrrolo [3, 2-d]pyrimidin-4-one derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | disclosed |
| US-7829707-B2 | neuroinflammatory, cardiovascular and respiratory disorders; inhibitors of Myeloperoxidase found predominantly in polymorphonuclear leukocytes; 1-butyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d]pyrimidin-4-one | ASTRAZENECA AB (SE) | 2010-11-09 | — | — | US | disclosed |
| US-20080221136-A1 | neuroinflammatory, cardiovascular and respiratory disorders; inhibitors of Myeloperoxidase found predominantly in polymorphonuclear leukocytes; 1-butyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d]pyrimidin-4-one | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| EP-1824855-A1 | NOVEL PYRROLO [3, 2-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006062465-A1 | NOVEL PYRROLO [3, 2-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099769-A1 | PYRROLO[3,2-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY | MPO, EPX, XDH | NPSR1 782/4885LDHA 685/4885AKR1C3 1361/4885 |
| US-20080221136-A1 | neuroinflammatory, cardiovascular and respiratory disorders; inhibitors of Myeloperoxidase found predominantly in polymorphonuclear leukocytes; 1-butyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d]pyrimidin-4-one | MPO, EPX, SERPINB1 | NPSR1 706/4885LDHA 1100/4885AKR1C3 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.